Showing 731-740 of 1922 results for "".
FDA Approves First Treatment for MacTel
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-approves-first-treatment-for-mactel/37075/The CEO of Neurotech joins us to talk about the FDA approval of the first treatment for MacTel; a target action date is set for Sydnexis’ pediatric myopia treatment candidate; and three eye care companies collaborate to launch a wearable vision testing platform. Learn more about your ad choices. VisHaag-Streit Launches METIS 900 Microscope
https://modernod.com/podcasts/eyewire-news-the-podcast/haag-streit-launches-metis-900-microscope/37074/Haag-Streit launches the METIS 900 ophthalmic microscope system; the FDA accepts Glaukos’ NDA for Epi-on cross-linking; and Optos releases its next generation ultra-widefield SLO imaging technology. Learn more about your ad choices. Visit megaphone.fm/adchoicesNew Myopia Software on Pentacam AXL
https://modernod.com/podcasts/eyewire-news-the-podcast/new-myopia-software-on-pentacam-axl/37073/Oculus launches new myopia software on its Pentacam AXL; the first clinical polygenic risk score test for glaucoma in the US is launched; and Virtual Vision Health releases visual acuity testing on its VR platform Learn more about your ad choices. Visit megaphone.fm/adchoicesAlcon Voyager DSLT Fully Launched in US
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-voyager-dslt-fully-launched-in-us/37072/Alcon launches the first DSLT device in thee US; the FDA approves an expanded label for Astellas Pharma's geographic atrophy drug Izervay; and New World Medical received FDA clearance for the VIA360 Surgical System. Learn more about your ad choices. Visit megaphone.fm/adchoicesAAO Opposes NIH Research Funding Proposal
https://modernod.com/podcasts/eyewire-news-the-podcast/aao-opposes-nih-research-funding-proposal/37071/The AAO responds to a proposal by the NIH to limit indirect funding for research projects; Lumenis launches a new device to address lower lid laxity and impaired blinking; and AI Optics receives FDA clearance for a handheld retinal imaging system. Learn more about your ad choices. Visit megaphone.fmFDA Approves Genentech's Susvimo Ocular Implant for DME
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-approves-genentechs-susvimo-ocular-implant-for-dme/37070/The FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoicesNorlase Launches First Pattern Scanning LIO
https://modernod.com/podcasts/eyewire-news-the-podcast/norlase-launches-first-pattern-scanning-lio/37069/The world’s first and only pattern scanning laser indirect ophthalmoscope is approved in the US and Europe; the European Commission approves a biosimilar to Eylea; and we review several clinical updates in the development of ophthalmic drugs. Learn more about your ad choices. Visit megaphone.fm/adchZeiss MEL 90 Approved by FDA
https://modernod.com/podcasts/eyewire-news-the-podcast/zeiss-mel-90-approved-by-fda/37068/Zeiss receives a major approval for its new excimer laser; Bausch + Lomb makes two deals to bolster its pipeline in glaucoma and geographic atrophy; and Rayner announces the full European launch of its RayOne Galaxy IOLs. Learn more about your ad choices. Visit megaphone.fm/adchoicesSpecial Report – Increasing Access to Care Through the Cure Blindness Project
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-increasing-access-to-care-through-the-cure-blindness-project/37067/Leaders from Cure Blindness Project discuss efforts to restore vision and prevent avoidable blindness in underserved communities around the world. Learn more about your ad choices. Visit megaphone.fm/adchoicesGlaukos Submits NDA for Epi-On CLX Candidate
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-submits-nda-for-epi-on-clx-candidate/37066/Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit m